Elsevier

Clinica Chimica Acta

Volume 436, 25 September 2014, Pages 237-242
Clinica Chimica Acta

Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests

https://doi.org/10.1016/j.cca.2014.05.019Get rights and content

Highlights

  • ACPA are part of the recent 2010 RA criteria.

  • The best combination for RA diagnosis is the use of APCA test together with IgA RF and IgG RF.

  • The source of antigen mainly determines the diagnostic performance of the ACPA test.

Abstract

ACPA (anti-citrullinated protein antibody) tests are today systematically added to clinical and radiological investigations when diagnosing rheumatoid arthritis (RA), and the inclusion of ACPA positivity in the new 2010 RA criteria underlines their importance.

The aim of this study was to determine the sensitivity and specificity of different ACPA assays and IgA, IgG and IgM isotypes of rheumatoid factor (RF) in a cohort of patients with early RA in order to assess the value of combining the tests. The serum samples were obtained from 46 RA patients, 80 patients with systemic rheumatic disease, and 20 blood donors. ACPAs were measured using five different commercial kits.

The receiver operating characteristic (ROC) curves of the anti-ACPA tests had area under the curve (AUC) values of 0.60–0.83. The diagnostic accuracy of the Bio-Rad multiplex flow immunoassay, a new technology for ACPA testing, was very similar to that of the other widely used commercial immunoassays. The EliA CCP-Phadia test was the most specific, and had the best positive likelihood ratio and positive predictive values, whereas the anti-CCP Inova 3.1 test was the most sensitive, and had the best negative likelihood ratio and negative predictive values.

The best combination to use for early RA screening was an ACPA test together with IgM and IgA RF.

Introduction

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease characterized by chronic joint inflammation (which often leads to the destruction of bone and cartilage) and the presence of autoantibodies, including rheumatoid factor (RF) and highly RA-specific anti-citrullinated protein antibodies (ACPAs usually measured as anti-CCP) [1]. It has been shown that RF and ACPA are present before the appearance of the clinical symptoms of arthritis, thus suggesting that the initial immune dysregulation occurs years before symptomatic disease [2]. It has also been shown that ACPAs are specific prognostic markers, and predict the erosive or non-erosive progression of the disease, thus making them useful for the optimal therapeutic management of RA patients [3].

Anti-keratin antibodies (AKAs) directed against fillagrin and anti-perinuclear factor (APF) have been historically described in RA patients, whereas ACPAs bind to citrullinated filaggrin, an epithelial protein containing citrulline residues as a result of post-translational modification [4]. In 1998, Shellekens et al. reported that AKAs recognize an epitope of citrullinated peptides in the serum of RA patients, and this led to the development of the first-generation ACPA test (designated anti-CCP), which used a mixture of CCP as a coating. However, its sensitivity was no more than 50%, and it was later replaced by second- and third-generation tests (CCP2 and CCP3), which used a mixture of synthetic cyclic peptides as a coating and increased sensitivity to 80% [5], [6]. The currently available ACPA assays use one of two synthetic peptide mixtures: CCP2 (Euro-Diagnostica) or CCP3 (Inova) [7]. The CCP2 peptide sequence was identified by screening highly complex peptide libraries using highly reactive serum taken from RA patients, whereas CCP3 was designed by means of combinatorial peptide engineering and contains multiple citrullinated epitopes in a conformational structure that increases epitope exposure and immunoreactivity, especially in the case of early RA [8]. Because of patent restrictions, most manufactures use the same synthetic peptide mixture as a coating, which means that the differences between them are more due to the method/instrument than the coating itself.

Today, ACPA tests are systematically added to clinical and radiological investigations when diagnosing RA, and the inclusion of ACPA positivity in the new 2010 RA criteria underlines their importance: RF and ACPAs together have a positive predictive value of nearly 100% [9].

The first international reference ACPA preparation has now been developed, an important step in reducing inter-laboratory and inter-method variability [10]. Furthermore, increasing demand has led a number of manufacturers to improve their own methods, which are mainly based on enzyme-linked immunosorbent assays (ELISAs), although a new multiplex flow immunoassay has recently been set up and shown very good concordance with ELISA [11].

The primary aim of this study was to determine the sensitivity and specificity of different ACPA assays and IgA, IgG and IgM isotypes of RF in a cohort of patients with early RA in order to assess the value of combining the tests [12], [13], [14]. The secondary aim was to compare the diagnostic sensitivity and specificity of the newly available ACPA assays with the previous tests.

Section snippets

Serum sampling

Serum samples were obtained from 46 patients with early RA diagnosed on the basis of the 2010 American College of Rheumatology (ACR) criteria (42 females and 4 males; mean age 65.2 ± 7.3 years; disease duration 1.5 [0.5–5.2] months) who attended the Rheumatology Unit of San Giovanni di Dio Hospital, Florence (Italy), between July 2011 and April 2012. Three of the patients were being treated with one or more immunosuppressants (methotrexate, sulfasalazine) and 43 with one of the biological drugs

Results

At the manufacturers' cut-off range values varied from 45.65% to 73.91% for diagnostic sensitivity and from 87% to 95% for diagnostic specificity.

The EliA CCP-Phadia test was the most specific of the APCA assays (95%), and had the best LR + and PPV, although the second best performers (Bio-Rad CCP and Axis-Shield CCP) were also very specific.

The EliA CCP-Phadia already reaches the 95% specificity at manufacturer cut-off, while others' cut-off already needs to be increased.

INOVA 3.1 was the most

Discussion

The recent addition of ACPA to RF testing in the 2010 RA classification criteria has reinforced the role of laboratory tests in RA diagnostics [9]. The later CCP3.1 version detects ACPA IgG + IgA, and is still the only assay approved by the American Food and Drug Administration (FDA) for the early detection of RA (510 k number: K072944).

Over the last few years, many studies have evaluated the diagnostic performance of ACPA assays using a variety of diagnostic platforms [15], [16], [17], [18], [19]

Conclusions

During last years the role of APCAs have been developed by new methods or by different diagnostic platforms such as fluorescence enzyme immunoassay (FEIA) and multiplex flow immunoassay (MFI).

MFI and FEIA technologies provide rapid results and are both totally automated. Their advantage over ELISAs is that it is possible to use a single sample run and gain constant random access, thus increasing efficiency and improving laboratory workflows.

New assays based on citrullinated proteins instead of

Conflicts of interest

The authors declare that they have no conflict of interest.

Authors' contributions

MI, MM, FA and MB contributed equally to the manuscript.

Acknowledgments

We gratefully aknowledge the technical assistance of R. Bambi, G. Ciotta, F. Priami, F. Soldaini, C. Taddei, and M. Valentini. We would like to thank Phadia AB-Upsala for the statistical analyses. All of the companies gifted their immunoassay kits.

References (35)

  • G.A. Schellekens et al.

    The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

    Arthritis Rheum

    (2000)
  • G.A. Schellekens et al.

    Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

    J Clin Invest

    (1998)
  • D. Aletaha et al.

    2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

    Arthritis Rheum

    (2010)
  • N. Bizzaro et al.

    Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies

    Ann Rheum Dis

    (2012)
  • A. Wu et al.

    A comparison of the BioPlex 200 anti-CCP assay and the Inova anti-CCP3 IgG assay: clinical sensitivity and specificity for rheumatoid arthritis

  • F. Debaugnies et al.

    Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis

    Scand J Rheumatol

    (2013)
  • N. Mutlu et al.

    Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid artrhritis

    J Rheumatol

    (2009)
  • Cited by (0)

    View full text